Dr. Bonny joins Enterome with 20 years' of medical research and industry experience with a strong background in drug discovery and pre-clinical development in the areas of inflammatory diseases and oncology. He was previously CSO at Bicycle Therapeutics in the UK and before that he worked at Switzerland-based Xigen where he served as CSO and President. Prior to Xigen, Dr. Bonny was Head of Research of the Medical Genetics Unit at the University Hospital of Lausanne, Switzerland. He obtained a Ph.D. in molecular biology from the University of Neuchâtel, Switzerland, and completed a business and entrepreneurship program at Babson College, US. Dr. Bonny is an author on over 100 scientific publications and is an inventor on multiple patents.
"Enterome has an exceptional opportunity to become a leading company developing innovative drugs and diagnostics based on its unrivalled understanding of the microbiome. In just a short time, Enterome has shown the power of its technology and is advancing its lead product, EB8018, which acts on a novel target in Crohn's Disease. I am excited to join the Company at a time of significant momentum and I look forward to working to further develop and advance Enterome's pipeline based on its world-class technologies and capabilities," said Christophe Bonny, Ph.D.
"At Enterome, we are taking a radically different approach from other microbiome companies to pin down well-defined novel targets and develop small molecules and diagnostic products based on our technology platform. We are very pleased to welcome Dr. Bonny to Enterome and l am sure he will make an important contribution as we look to build a pipeline of novel therapeutic products based on our 'drugs from bugs' approach," said Pierre Belichard, CEO of Enterome. "Enterome is at an important inflexion point as we look to leverage our technology, knowledge and industry partnerships to become one of the leading microbiome companies globally."
Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel diseases; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €32 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and strategic investors (Nestlé Health Science, Shire & INRA transfer).
Additional information about Enterome is available through its website: www.enterome.com